Vis enkel innførsel

dc.contributor.authorObuobi, Sybil Akua Okyerewa
dc.contributor.authorPhung, Anna Ngoc
dc.contributor.authorJulin, Kjersti
dc.contributor.authorJohannessen, Mona
dc.contributor.authorSkalko-Basnet, Natasa
dc.date.accessioned2022-01-24T09:34:11Z
dc.date.available2022-01-24T09:34:11Z
dc.date.issued2021-12-16
dc.description.abstractTo avert the poor bioavailability of antibiotics during S. aureus biofilm infections, a series of zwitterionic nanoparticles containing nucleic acid nanostructures were fabricated for the delivery of vancomycin. The nanoparticles were prepared with three main lipids: (i) neutral (soy phosphatidylcholine; P), (ii) positively charged ionizable (1,2-dioleyloxy-3-dimethylaminopropane; D), and (iii) anionic (1,2-dipalmitoyl-sn-glycero-3-phospho((ethyl-1′,2′,3′-triazole) triethylene glycolmannose; M) or (cholesteryl hemisuccinate; C) lipids. The ratio of the anionic lipid was tuned between 0 and 10 mol %, and its impact on surface charge, size, stability, toxicity, and biofilm sensitivity was evaluated. Under biofilm mimicking conditions, the enzyme degradability (via dynamic light scattering (DLS)), antitoxin (via DLS and spectrophotometry), and antibiotic release profile was assessed. Additionally, biofilm penetration, prevention (in vitro), and eradication (ex vivo) of the vancomycin loaded formulation was investigated. Compared with the unmodified nanoparticles which exhibited the smallest size (188 nm), all three surface modified formulations showed significantly larger sizes (i.e., 222–277 nm). Under simulations of biofilm pH conditions, the mannose modified nanoparticle (PDM 90/5/5) displayed ideal charge reversal from a neutral (+1.69 ± 1.83 mV) to a cationic surface potential (+17.18 ± 2.16 mV) to improve bacteria binding and biofilm penetration. In the presence of relevant bacterial enzymes, the carrier rapidly released the DNA nanoparticles to function as an antitoxin against α-hemolysin. Controlled release of vancomycin prevented biofilm attachment and significantly reduced early stage biofilm formations within 24 h. Enhanced biocompatibility and significant ex vivo potency of the PDM 90/5/5 formulation was also observed. Taken together, these results emphasize the benefit of these nanocarriers as potential therapies against biofilm infections and fills the gap for multifunctional nanocarriers that prevent biofilm infections.en_US
dc.identifier.citationObuobi, Phung, Julin, Johannessen, Skalko-Basnet. Biofilm Responsive Zwitterionic Antimicrobial Nanoparticles to Treat Cutaneous Infection. Biomacromolecules. 2021:1-13en_US
dc.identifier.cristinIDFRIDAID 1969967
dc.identifier.doi10.1021/acs.biomac.1c01274
dc.identifier.issn1525-7797
dc.identifier.issn1526-4602
dc.identifier.urihttps://hdl.handle.net/10037/23776
dc.language.isoengen_US
dc.publisherAmerican Chemical Societyen_US
dc.relation.journalBiomacromolecules
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleBiofilm Responsive Zwitterionic Antimicrobial Nanoparticles to Treat Cutaneous Infectionen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel